Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$TNDM Q4 '24 Earnings Results & Recap Tandem Diabetes' Q4'24 results showed EPS of $0.01 (beating expectations of -$0.21), and revenue of $252.45M (beating expectations of $250.58M). The company anticipates 10-11% worldwide sales growth in 2025, with key drivers including the new Control IQ Plus algorithm and expansion into the pharmacy market, though potential headwinds remain due to the transition to direct sales in Europe.
3

Since Post

Full Details

Advertisement|Remove ads.